**Online Supplementary Table 2**

|  |  |  |  |
| --- | --- | --- | --- |
| **Risk factor and condition**  | **Rate (%)** | **Country**  | **Author Year**  |
| High TSB, transient ‘BE”, abnormal ABR | 34% | USA | Amin 2005 |
| High TSB, ‘ABE”  | 8.5% | USA | Kuzniewisc 2016 |
| “Severe hyperbilirubinaemia”  | 14.7% | Australia  | McGillivray 2018 |
| High TSB, “BE” | 14%, 30%  | Egypt  | Gamaleldin 2011, Iskander 2014 |
| High TSB, “ABE”  | 22% | Iraq | Hameed 2001 |
| High TSB, “ABE”  | 44%  | India  | Kumar 2016 |
| ABO incompatibility, “ABE” | 348 in a year | China  | Subspeciality 2012 |
| ABO incompatibility, “ABE” | 53%  | China  | Yu 2017  |
| High TSB, “BE”  | 3.8% | Iran  | Arkadani 2011 |
| High TSB needing phototherapy, “ABE” | 21.2% | Myanmar  | Arnolda 2015 |

**Table 2: Selected references on the incidence of conditions covered in the spectrum of Kernicterus Spectrum Disorder (KSD) among high-risk groups in different countries.**

**\*ABE: acute bilirubin encephalopathy, BE: bilirubin encephalopathy**

**References**

1. Sgro M, Kandasamy S, Campbell DM, Ofner M. Comparing rate of severe neonatal hyperbilirubinemia in three Western industrialized populations: Canada, the United Kingdom & Ireland, and Switzerland. Paediatrics and Child Health (Canada). 2014;19(6):e92-e3.

2. Amin SB, Charafeddine L, Guillet R. Transient bilirubin encephalopathy and apnea of prematurity in 28 to 32 weeks gestational age infants. Journal of perinatology : official journal of the California Perinatal Association. 2005;25(6):386-90.

3. Kuzniewicz MW, Wickremasinghe AC, Wu YW, McCulloch CE, Walsh EM, Wi S, et al. Incidence, etiology, and outcomes of hazardous hyperbilirubinemia in newborns. Pediatrics. 2014;134(3):504-9.

4. McGillivray AJ, Polverino J, Badawi N, Evans N. Long-term neurodevelopmental outcomes following extreme neonatal hyperbilirubinaemia in Australian infants born between 2010 and 2013. Journal of Paediatrics and Child Health. 2018;54:91.

5. Gamaleldin R, Iskander I, Seoud I, Aboraya H, Aravkin A, Sampson PD, et al. Risk factors for neurotoxicity in newborns with severe neonatal hyperbilirubinemia. Pediatrics. 2011;128(4):e925-31.

6. Hameed NN, Na' Ma AM, Vilms R, Bhutani VK. Severe neonatal hyperbilirubinemia and adverse short-term consequences in Baghdad, Iraq. Neonatology. 2011;100(1):57-63.

7. Iskander I, Gamaleldin R, El Houchi S, El Shenawy A, Seoud I, El Gharbawi N, et al. Serum bilirubin and bilirubin/albumin ratio as predictors of bilirubin encephalopathy. Pediatrics. 2014;134(5):e1330-9.

8. Kumar M, Tripathi S, Singh SN, Anand V. Outcome of neonates with severe hyperbilirubinemia in a tertiary level neonatal unit of North India. Clinical Epidemiology and Global Health. 2016;4(2):51-6.

9. Subspecialty Group of N, Society of Pediatrics CMA, Chinese Multicenter S, Coordination Group for Neonatal Bilirubin E. [Clinical characteristics of bilirubin encephalopathy in Chinese newborn infants-a national multicenter survey]. Zhonghua er ke za zhi Chinese journal of pediatrics. 2012;50(5):331-5.

10. Yu C, Li H, Zhang Q, He H, Chen X, Hua Z. Report about term infants with severe hyperbilirubinemia undergoing exchange transfusion in Southwestern China during an 11-year period, from 2001 to 2011. PLoS One. 2017;12(6):e0179550.

11. Ardakani SB, Dana VG, Ziaee V, Ashtiani MT, Djavid GE, Alijani M. Bilirubin/Albumin Ratio for Predicting Acute Bilirubin-induced Neurologic Dysfunction. Iranian journal of pediatrics. 2011;21(1):28-32.

12. Arnolda G, Nwe HM, Trevisanuto D, Thin AA, Thein AA, Defechereux T, et al. Risk factors for acute bilirubin encephalopathy on admission to two Myanmar national paediatric hospitals. Maternal health, neonatology and perinatology. 2015;1:22.